Analyst upgrades typically lead to a positive short-term reaction in the stock market as they reflect a bullish view on the company's future earnings potential and growth prospects. The significant raise in price target to $180 by a reputable analyst firm like Oppenheimer suggests a strong conviction in Sarepta Therapeutics' value and potential, likely influencing investor sentiment and stock price positively in the short term.